New cocktail shows promise for Tough-to-Treat colorectal cancer
NCT ID NCT04109924
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested a combination of three drugs—TAS-102, irinotecan, and bevacizumab—in 42 people with advanced colorectal cancer that had spread or couldn't be removed. The goal was to see if this mix could slow tumor growth better than standard treatments. Participants received the drugs intravenously and by mouth in cycles, and researchers measured how long the cancer stayed under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TAS-102, irinotecan, and bevacizumab
What this could lead to
If this works, it could provide a new treatment option for people with advanced colorectal cancer who have already tried standard therapies.
What could go wrong
This is a small, early-phase study (42 people) without a comparison group, so results may not apply broadly. The drug combination can cause side effects like low blood counts and diarrhea.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III RECTAL CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States